Tejara Capital Ltd reported 5.3% ownership of Cardiol Therapeutics, representing 6,382,551 Class A common shares. The position is certified as held in the ordinary course and not for changing or influencing control, giving investors the stated basis for its passive classification.
Key Highlights
- Tejara Capital Limited manages Trefoil Select Funds SPC-Stylus SP, which is registered in Cayman.
- Miyan Mansur Mannan signed the ownership report as director on Sep 23, 2026.
- Tejara undertook to provide Commission staff with requested information under the certification.
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a biotechnology company. Tejara Capital Ltd reported ownership of 5.3% of Cardiol Therapeutics, covering 6,382,551 Class A common shares. The position was described as held in the ordinary course without an intent to change or influence control.
Tejara Reports 6,382,551 Class A Shares
Tejara Capital Limited is authorised by the FCA in the United Kingdom as a fund manager. The reported position relates to Trefoil Select Funds SPC-Stylus SP, which is registered in Cayman. The ownership information appears on a Schedule 13G/A under Rule 13d-1(b). The report identifies 5.3% ownership of Cardiol Therapeutics.
Passive Ownership Certification
The certification says the securities were acquired and held in the ordinary course of business. It also states that the position was not acquired or held to change or influence Cardiol Therapeutics’ control, nor in connection with a transaction intended to do so. Tejara further certified that the UK regulatory framework applying to an FCA-authorised Fund Manager is substantially comparable to the corresponding U.S. framework.
FAQs
Q: How many Cardiol Therapeutics shares does Tejara Capital report?
A: Tejara Capital reports 6,382,551 Class A common shares of Cardiol Therapeutics. That holding represents 5.3% ownership in the biotechnology company.
Q: Is Tejara Capital’s Cardiol Therapeutics stake passive?
A: Yes. Tejara Capital’s 5.3% stake was acquired and held in the ordinary course of business, without intent to change or influence Cardiol Therapeutics’ control.
Q: Which fund is linked to Tejara Capital’s Cardiol Therapeutics position?
A: The reported position is connected with Trefoil Select Funds SPC-Stylus SP. The fund is registered in Cayman, while Tejara Capital manages it.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.